Table 2.

Baseline and repeated biomarker measurements in relation to clinical outcome.

Biomarker	Baseline measurement								Repeated measurements
	Unadjusted		Adjusted for age and sex		Adjusted for clinical variables*		Adjusted for biomarkers**		Unadjusted		Adjusted for age and sex		Adjusted for clinical variables *		Adjusted for biomarkers**
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Albumin	3.25 (0.31; 34.20)	0.32	1.24 (0.10; 15.54)	0.86	1.65 (0.15; 17.92)	0.68	0.47 (0.05; 4.93)	0.53	1.85 (1.18; 2.98)	0.007	1.37 (1.05; 1.80)	0.014	1.001 (0.996; 1.005)	0.79	1.14 (1.09; 1.20)	< 0.001
Bilirubin	1.41 (1.02; 1.96)	0.04	1.44 (1.01; 2.05)	0.04	1.25 (0.88; 1.78)	0.21	1.12 (0.80; 1.56)	0.51	2.76 (1.94; 3.96)	< 0.001	3.47 (2.31; 5.35)	< 0.001	1.06 (1.02; 1.11)	0.004	1.98 (1.32; 2.95)	0.002
ALP	2.53 (1.69; 3.81)	< 0.001	2.40 (1.60; 3.59)	< 0.001	2.58 (1.70; 3.94)	< 0.001	1.47 (0.98; 2.18)	0.06	3.64 (2.26; 5.55)	< 0.001	3.59 (2.23; 6.28)	< 0.001	1.13 (1.07; 1.19)	< 0.001	1.84 (1.09; 3.05)	0.018
GGTP	1.42 (1.17; 1.74)	< 0.001	1.43 (1.17; 1.76)	< 0.001	1.32 (1.08; 1.62)	0.007	1.21 (1.00; 1.46)	0.05	1.58 (1.29; 1.95)	< 0.001	1.60 (1.29; 2.00)	< 0.001	1.03 (1.01; 1.06)	0.001	1.33 (1.08; 1.63)	0.006

Hazard ratio (HR) and 95% confidence interval (CI) is given per doubling of bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGTP) level and halving of albumin level; new p value threshold after Bonferroni correction = 0.0125;

^*covariates include: systolic blood pressure, New York Heart Association class III or IV, duration of chronic heart failure (years), diabetes mellitus;

^**biomarkers include baseline N-terminal prohormone B-type natriuretic peptide (NT-proBNP), baseline high sensitivity troponin T (hs-TnT)